Abstracts tagged "glucocorticoids"

Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1420 • 2014 ACR/ARHP Annual Meeting
Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR
Salvador Loredo-Alanís¹, David Vega-Morales², Mario Garza-Elizondo¹, Mario Garcia-Pompermayer³, Roberto Negrete-López¹, Daniel Treviño-Montes¹ and Diana Flores-Alvarado², ¹Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ³Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico
Background/Purpose The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in…
Abstract Number: 1211 • 2014 ACR/ARHP Annual Meeting
Gene Expression Profile in Muscle Tissue before and after Immunosuppressive Treatment in Patients with Myositis
Joan Raouf¹, Ingela M. Loell², Yi-Wen Chen³, Rongye Shi⁴, Inger Nennesmo⁵, Helene Alexanderson⁶, Maryam Dastmalchi², Marina Korotkova⁷, Kanneboyina Nagaraju^8,9 and Ingrid E. Lundberg^10,11, ¹Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, ⁴Research Center for Genetic Medicine, Childrens National Medical Center, Research Center for Genetic Medicine, Washington DC, USA, Washington DC, WA, ⁵Institution for Laboratory Medicine (LABMED), Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden, Stockholm, Sweden, ⁶Karolinska Institutet, Department of medicine, Rheumatology Unit, Karolinska Universitetssjukhuset Solna, Stockholm, Sweden, Stockholm, Sweden, ⁷Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Genetic Medicine, Children's National Medical Center, Washinton D C, DC, ⁹Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, ¹⁰Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Autoimmune muscle diseases such as polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of inflammatory cells, production of cytokines and chemokines, as well…
Abstract Number: 1118 • 2014 ACR/ARHP Annual Meeting
Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections
Kyriakos A. Kirou¹ and Naveed Chaudhry², ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose . Olecranon bursitis is a common presentation to an outpatient rheumatology practice. The differential diagnosis includes crystalline bursitis (gout and pseudogout), inflammatory bursitis due…
Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Akhila Balasubramanian¹, Sally Wade², Robert A Adler³, Celia Fang (Lin)⁴, Michael Maricic⁵, Cynthia O'Malley¹, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁴Amgen, Thousand Oaks, CA, ⁵Catalina Pointe Rheumatology, Tucson, AZ, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…
Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 29 • 2014 ACR/ARHP Annual Meeting
Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Annemarie Lang¹, Sarah Fuegener², Paula Hoff², Anastasia Rakow³, Manuela Jakstadt⁴, Timo Gaber⁴, Gerd Burmester², Carsten Perka³ and Frank Buttgereit⁵, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Center for Musculoskeletal Surgery, Orthopedic Department, Charité University Medicine, Berlin, Germany, ⁴Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose Anti-inflammatory treatment of rheumatoid arthritis (RA) with glucocorticoids (GC) and/or non-steroidal anti-inflammatory drugs (NSAIDs) is supposed to negatively influence bone metabolism and healing. It…
Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting
Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial
Kichul Shin¹, Sung-Hwan Park², Won Park³, Han Joo Baek⁴, Yun Jong Lee⁵, Seong-Wook Kang⁶, Jung-Yoon Choe⁷, Wan-Hee Yoo⁸, Yong-Beom Park⁹, Jung-Soo Song¹⁰, Bin Yoo¹¹, Dae-Hyun Yoo¹² and Yeong Wook Song¹³, ¹Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁷Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹⁰Rheumatology, Chung-Ang Univ Hospital, Seoul, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…
Abstract Number: 55 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Receptor Modulator Compound A Does Not Induce Leptin In Human Osteoarthritic Synovial Fibroblasts and In Dedifferentiated Chondrocytes
Olivier Malaise¹, Biserka Relic², Edith Charlier¹, Mustapha Zeddou¹, Florence Quesada-Calvo³, Sophie Neuville⁴, Dominique de Seny² and Michel G. Malaise², ¹Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ²Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³Gastroenterology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ⁴GIGA Research - University of Liège - CHU of Liège, Liège, Belgium
Background/Purpose: Leptin is generally considered detrimental in osteoarthritis (OA) as it can induce IL-8 in synovial fibroblasts (SF) and matrix metalloproteinases in chondrocytes. We recently…
Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Kim Hørslev-Petersen¹, Merete Lund Hetland², Peter Junker³, Jan Pødenphant⁴, Torkell Ellingsen⁵, Palle Ahlqvist⁶, Hanne M. Lindegaard⁷, Asta Linauskas⁸, Annette Schlemmer⁹, Mette Y. Dam¹⁰, Ib Hansen¹¹, Tine Lottenburger⁶, Anette Jørgensen¹², Sophine B. Krintel¹³, Johnny Raun¹⁴, Christian G. Ammitzbøll¹⁰, Julia Johansen¹³, Mikkel Østergaard¹⁵ and Kristian Stengaard-Pedersen¹⁰, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University at Gentofte, Hellerup, Denmark, ⁵Silkeborg Regional Hospital, Silkeborg, Denmark, ⁶University of Southern Denmark, Vejle, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Vendsyssel Hospital, Hjørring, Denmark, ⁹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Arhus University Hospital, Aarhus, Denmark, ¹¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹³Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁴University of Southern Denmark, Graasten, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…
Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Thomas Stock¹, Dona Fleishaker², Xin Wang², Arnab Mukherjee² and Charles Mebus², ¹Pfizer Inc., Collegeville, PA, ²Pfizer Inc., Groton, CT
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Jayesh Pandya¹, Ingela M. Loell², Mohammad Shahadat Hossain², Mei Zong², Sukanya Raghavan², Ingrid E. Lundberg³ and Vivianne Malmström², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…
Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
P.H.P. de Jong¹, J.M.W. Hazes², K.H. Han³, A.M. Huisman⁴, D. van Zeben⁵, P.A. van der Lubbe⁶, A.H. Gerards⁶, B. van Schaeybroeck⁷, P.B. de Sonnaville⁸, M.V. Krugten⁹, J.J. Luime² and A.E.A.M. Weel³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
Abstract Number: 1663 • 2013 ACR/ARHP Annual Meeting
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Marco A. Cimmino¹, Bhaskar Dasgupta², Cynthia S. Crowson³, Michael Schirmer⁴, Christian Dejaco⁵, Carlo Salvarani⁶ and Eric L. Matteson⁷, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ⁵Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁶Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Obesity is not only a risk factor for osteoarthritis but also for rheumatoid arthritis (RA). In obese RA patients, disease incidence is higher and…
Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Toshihisa Kojima¹, Nobunori Takahashi², Koji Funahashi³, Shuji Asai¹, Masahiro Hanabayashi¹, Shinya Hirabara⁴, Nobuyuki Asai⁵ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁵Nagoya Univeristy Hospital, Nagoya, Japan
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].